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Abstract  
Hepatocellular carcinoma (HCC) is a major cause of cancer worldwide. Proteomic studies 
provide opportunities to uncover targets for the diagnosis and treatment of this disease. However, 
in HCC developing in a setting of cirrhosis, the detection of proteome alterations may be 
hampered by the increased cellular heterogeneity of tissue when analyzing global liver 
homogenates. The aim of this study was to evaluate whether the identification of proteome 
alterations in these HCC cases was improved when the differential protein profile between 
tumour and non-tumour areas of liver was determined using hepatocytes isolated by laser 
microdissection (LM). Differential profiles established with LM-hepatocytes and liver section 
homogenates using 2-DE and mass spectrometry exhibited noticeable differences: 30% of the 
protein spots with deregulated expression in tumorous LM-samples did not display any 
modification in homogenates; conversely 15% of proteins altered in tumorous homogenates were 
not impaired in LM-hepatocytes. These alterations resulted from the presence in cirrhotic liver of 
fibrotic stroma which displayed a protein pattern different from that determined in LM-
hepatocytes. In conclusion, our data demonstrate the interest of LM in distinguishing between 
fibrotic and hepatocyte proteome alterations and thus the benefit of LM to proteome studies of 
HCC developing in a context of cirrhosis. 
 
 
  
 
 
1- Introduction 
Hepatocellular carcinoma (HCC) is an important cause of cancer worldwide [1] and its incidence 
is increasing markedly in North America and Europe [2]. Chronic infections due to hepatitis C 
(HCV) and hepatitis B (HBV) viruses are the principal etiological factors. Thus, in most cases, 
HCC develops in a context of cirrhosis resulting from chronic inflammatory liver disease. The 
treatment options for HCC remain limited: surgery is only feasible at an early stage of the disease 
and is often ineffective because of frequent tumour recurrence; cytotoxic agents have only a 
limited impact on tumour progression. Patients at risk are routinely screened for serum alpha-
fetoprotein and examined using imaging techniques. Both procedures are informative for large 
tumours. However the specificity of serum AFP levels is poor, especially against a background of 
chronic hepatitis [3]. Thus the cancer is generally advanced when finally diagnosed. Other 
approaches therefore need to be adopted to identify novel markers which will enable an earlier 
diagnosis of HCC and the development of novel therapies in order to improve patient survival.  
Proteomics have provided opportunities to uncover new targets for the diagnosis and treatment of 
HCC [4-6]. Two-dimensional electrophoresis (2-DE) and mass spectrometry are tools which are 
widely employed to identify proteome alterations, and have been used to study proteome 
alterations in HCC developing in a setting of cirrhosis [7-13].  However, a comparative analysis 
of the published data had led to the identification of few common deregulated proteins 
(unpublished observations). Several reasons could be put forward to explain these findings; one is 
that these studies targeted patients with varying causes (hepatitis B or C, alcohol consumption, 
metabolic disorders) for their liver disease which displayed different degrees of severity. During 
these investigations, the protein profile of tumorous tissue was compared with that of paired 
cirrhotic tissue. Whereas tumours were mostly homogeneous, and usually macroscopically 
  
 
 
dissected from the surrounding stroma with ease, the cirrhotic tissue displayed significant cellular 
heterogeneity. Regenerating hepatocyte nodules were embedded in fibrotic tissue (fibroblasts, 
inflammatory cells, etc.) which could hamper the accurate detection of proteins with deregulated 
expression in tumorous hepatocytes. 
Laser microdissection (LM) has been developed for the selective isolation of enriched target cell 
populations in heterogeneous tissues [14, 15]. Proteins extracted from LM-procured cells have 
been demonstrated to be suitable for analysing proteome alterations using 2-DE in several tissues 
[16-20]. With respect to liver tissue, the precise experimental procedures, as well as the benefits 
of LM in protein profiling studies, have been little documented to date [21-23]. 
The aim of the present study was therefore to define a reliable experimental approach and to 
evaluate the benefits of using LM-hepatocytes when analysing proteomic alterations in HCC 
developing in a context of cirrhosis. 
  
 
 
 
2- Materials and methods 
2.1-Tissue specimens  
Hepatectomy specimens were obtained via the French National Collection of Hepatocellular 
Carcinoma (INSERM) [24]  from three HCV-infected patients whose HCC had developed in a 
setting of cirrhosis (two males and one female, with a mean age of 75 years). None of the patients 
was hepatitis B surface antigen-positive. Tissue areas were viewed macroscopically, and those 
deemed to contain HCC tissues and their paired adjacent cirrhotic tissues were selected by a 
specialist pathologist, preserved by snap freezing in liquid nitrogen and stored at –80°C. For 
microscopic examination, 5µm thick frozen sections were cut onto slides, stained using a 
standard haematoxylin & eosin method and examined by a pathologist.  
2.2-Laser Capture Microdissection and protein solubilisation  
Briefly, 8µm frozen tissue sections were fixed for 1 min with 70% ethanol, stained with Mayer’s 
haematoxylin for 30 sec immersed in Scott’s tap water and then in eosin (0.25% in an alcohol 
solution) for 10 sec each. The sections were then dehydrated in graded ethanol solutions (70% for 
30 sec and 100% for 1 min), incubated in xylene (2 x 5 min) and air dried. Each aqueous solution 
contained Complete Protease Inhibitor Cocktail (Roche Biochemicals France).  
Tumorous and non-tumorous cirrhotic nodules were microdissected with a PixCell II System 
(Arcturus Engineering Inc. USA) (Supplemental Data section: Figure 1). For each sample, 
approximately 100,000 – 150,000 cells were captured on multiple caps; moreover, from the same 
liver sections, we also specifically microdissected fibrotic areas and hepatocytes located within 
cirrhotic nodules. A maximum time for microdissection was fixed at 20 min per slide. After 
capture, the caps were cleared of non-specifically adhering tissue using an adhesive pad (CapSure 
  
 
 
Cleanup Pad, Arcturus Engineering Inc. USA) and stored at -80°C until use. LM-hepatocytes, 
together with stained tissue sections and microdissected stroma, were solubilised in lysis buffer 
(7M urea, 2M thiourea, 4% CHAPS, 0.5% Pharmalyte 3-10 (Amersham Biosciences), 1% DTT). 
Protein lysates were centrifuged at 100,000 x g for 30 min and supernatants were stored at -80°C 
until use. The concentration of solubilised proteins in samples was measured using the RC-DC 
assay kit (Biorad France). 
 
2.3-2 DE and image analysis  
One hundred and twenty micrograms of protein were used for each electrophoretic run. 
Hepatocyte lysates from the three patients were analysed as pooled extracts (40 micrograms of 
protein per patient). IEF were performed onto 18 cm pH 5-8 IPG strips previously rehydrated for 
14 hours in lysis buffer using cup loading strip holders (IPGphor apparatus, Amersham 
Biosciences). Focusing was carried out for 11h 30 min with a total of 31kVh. SDS-PAGE (10% 
polyacrylamide gels) was performed using an Ettan Dalt II apparatus (Amersham Biosciences) 
according to the manufacturer’s instructions. For each condition (LM-hepatocytes or tissue 
sections) tumorous and non-tumorous counterparts were processed during the same experiments. 
The 2-DE gels were stained using a standard silver staining. Spot detection and the quantification 
of spot signals based on their relative volume were carried out using ImageMaster 2D Platinum 
software (Amersham Biosciences). Triplicate 2-DE were performed for each sample and the 
reproducibility of protein profiles was assessed by establishing Spearman correlation coefficients 
between these three profiles. In all cases, the range of this coefficient was between 0.8 and 0.92 
(p<0.01). A synthetic gel containing all protein spots present in 2-DE, carried out with tumorous 
and non-tumorous samples, was constructed in order to assign coordinates and accession number 
to each spot present in the different gels. The differential protein expression profiles between 
  
 
 
tumorous and non-tumorous counterparts in both LM and homogenates samples were established 
by comparing the relative volumes of spots with the same accession numbers in different gels. 
Statistical analysis was performed using the Mann Whitney U-test and Student’s t-test.  The 
expression ratios of each spot using the two methods were compared using the match-paired 
Wilcoxon rank test.  
 
2.4-Identification of protein spots using mass spectrometry  
Protein identification was conducted according to an “in-gel” digestion procedure [26, 27]. 
Briefly, 2-DE gels (120 µg protein) were stained using the PlusOne Silver Staining Kit 
(Amersham Biosciences) without glutaraldehyde. Protein spots of interest were excised from the 
gels and submitted to trypsin digestion overnight at 37°C. The peptides recovered were dissolved 
in 50% ACN and 0.1% TFA, mixed with HCCA matrix (Bruker Daltonics, France) and then 
analysed using a MALDI-TOF mass spectrometer (AutoFlex; Bruker Daltonics France). The 
acquired spectra were processed using FlexAnalysis software (Bruker Daltonics France). Peptide 
masses were screened against the SwissProt database using Mascot Software (Matrix Science, 
London). In order to achieve confident identifications, we only included statistically significant 
Mascot scores (p<0.05). 
 
2.5-Western blot analysis  
Protein samples were resolved by SDS-PAGE and transferred to nitrocellulose membrane by 
means of electroblotting. Membranes were blocked in 5% non-fat dried milk in 25 mM Tris pH 
7.5, 150 mM NaCl, 0.1% Tween 20, incubated with appropriate primary antibodies (GRP 75, 
Stressgen Bioreagents/Tebu Bio Paris France; MxA, gift from B. Horisberger, Basle, 
Switzerland; mitochondrial HMG-CoA synthase, gift from P. Quant, London, UK; Annexin A1, 
  
 
 
clone EH17A and arginase I antibodies from Santa Cruz Biotechnology/TebuBio,  France; tissue 
transglutaminase fromLabVision/Interchim, France; Cathepsin D from Abcam. France; 
nicotinamide N-methyltransferase from Genway Biotech inc. USA)   and then with the 
appropriate secondary antibodies. Protein bands were visualised using enhanced 
chemiluminescence (Amersham Biosciences). After each analysis, the membrane was stripped 
using a Restore kit (Pierce). Equal loading was confirmed by Ponceau S staining of the blots. 
  
 
 
 
3-Results 
3.1-Determination of optimum haematoxylin/eosin staining procedures. 
The accurate microdissection of hepatocyte clusters in cirrhotic liver requires the staining of 
tissue slides in order to eliminate stromal and inflammatory cells. In our experience, 
haematoxylin/eosin (H/E) is the only reference method appropriate for the microscopic 
characterization of liver cells. Haematoxylin/eosin coloration procedures chosen for the standard 
microscopic examination of liver sections or for nucleic acid studies using LM-hepatocytes [25, 
28] are not suitable for proteomic studies: under these staining conditions the protein recovery 
from tissue sections was seen to be impaired and 2D-PAGE profiles determined with 
homogenates obtained using these tissue sections were altered ([29] and results not shown).  We 
thus sought to determine experimental conditions which could combine haematoxylin/eosin 
staining and correct protein profiling. Briefly, the length of the overall staining procedure was 
strongly reduced and the minimum concentration of eosin (0.25% in ethanol) which allowed the 
correct identification of liver cells in the presence of haematoxylin was determined. Under these 
conditions (Figure 1A), the 2-DE profiles obtained with unprocessed, stained and microdissected 
liver slides were similar, suggesting that overall, the treatments undergone by tissue slides did not 
have a significant impact on protein profiling. To check this point, calculated means for matched 
spots from the three gels in each group were used to determine correlations between the different 
groups. As shown in Figure 1B, there was a significant correlation between the relative volumes 
of spots from both unprocessed and stained slides (r=0.92; p<0.01; slope=0.96) and from stained 
slides and stained microdissected slides (r=0.87; p<0.01; slope=1.06). 
 
  
 
 
3.2-Comparison of differential protein profiles between LM-hepatocytes and global liver 
homogenates  
Two-DE performed on microdissected hepatocytes and total liver homogenates were carried out 
using pooled samples from three patients. Eight hundred and fifty and 800 protein spots were 
detected under 2DE performed on entire liver sections (referred to as homogenates) and 
microdissected hepatocyte-enriched fractions (referred to as LM-hepatocytes), respectively. 
Among these spots, 786 were detected as having the same coordinates in both samples. Of these 
786 spots, 146 were altered in tumorous LM-hepatocytes (72 were over-expressed and 74 under-
expressed) and 119 in tumorous homogenates (63 were over-expressed and 56 under-expressed), 
as compared to their respective non tumorous counterparts (tumour vs. non-tumour: p<0.05). 
Data are listed in the Table of Supplemental Data. 
Among the 146 protein spots deregulated in tumorous LM-hepatocytes, 95 exhibited a similar 
deregulation pattern in homogenate-based experiments (Figure 2).  By contrast, the expression 
pattern differed in 51 of these 146 spots: 8 exhibited a reverse modulation and 43 showed no 
modification in tumorous homogenates. On the other hand, among the 119 protein spots 
deregulated in tumorous homogenates, 16 were not altered in LM-hepatocyte-based experiments. 
To further investigate these discrepancies between LM- and homogenate-based experiments, we 
compared the relative volumes of the 67 spots which displayed different expression patterns in 
homogenates and LM-hepatocytes (Figure 3). Forty eight of these 67 spots only showed different 
relative volumes in LM- and homogenate-derived non-tumorous samples.  By contrast, 
differences in alterations to the remaining 19 spots were only observed between LM- and 
homogenate-derived tumorous samples.  
3.3-Identification of deregulated proteins in tumorous samples  
  
 
 
Protein spots exhibiting differential expression between tumour and non-tumour areas during 
experiments performed with LM-hepatocytes and/or homogenates were identified using MALDI-
MS.  The same proteins were identified from protein spots with the same coordinates, picked 
from 2-DE procedures carried out with LM-hepatocytes and homogenates. Forty five different 
proteins were identified with confidence (peptide coverage, significant Mascot score; p<0.05) 
from spots determined by 2-DE performed on tumorous and non-tumorous LM-hepatocytes 
(Table 1). A failure to identify some protein spots (18 of the 67 picked spots) was associated with 
the poor peptide spectra acquired which probably reflected their low abundance; indeed, in most 
cases, these protein spots were weakly silver stained.  
In order to reinforce the data obtained during comparative analysis of the differential protein 
profiles determined using LM-hepatocytes and homogenates, we used Western blot to analyse 
proteins whose expression pattern in tumour varied under the two conditions studied (Figure 4). 
As observed during 2-DE experiments, Annexin A1 was decreased and GRP 75 increased under 
both conditions. On the other hand (and as had been determined during the first part of this study) 
we found that mitochondrial HMG-CoA synthase and MxA were not deregulated in tumorous 
homogenates, whereas expression of these proteins was decreased in tumorous LM-hepatocytes.  
To further demonstrate the value of LM to distinguishing between fibrotic and hepatocyte 
proteome alterations, we used microdissection to isolate hepatocytes and fibrotic stroma in non 
tumorous areas from two patients (Figure 5A). The expression of arginase 1 and mitochondrial 
HMG CoA synthase was analysed in these two compartments, as well as in the entire non-
tumorous liver section. As shown in Figure 5B, we found that the expression of both proteins 
clearly differed between fibrotic stroma and hepatocytes: arginase 1 and mitochondrial HMG 
CoA synthase expression was reduced in the fibrotic stroma when compared with the level in 
hepatocytes.  Similarly, the expression of MxA, cathepsin D, nicotinamide N-methyltransferase 
  
 
 
and tissue transglutaminase was markedly reduced in the fibrotic stroma when compared with 
hepatocytes.  Data are presented in the Supplemental data section (Figure 2)  
 
 
4-Discussion 
Cellular heterogeneity is a critical issue when investigating HCC proteome, given the frequent 
association of the tumour with cirrhosis. In combination with different downstream analyses, 
microdissected cells have made it possible to perform genome and transcriptome-based analyses 
which have highlighted new pathogenic mechanisms in several diseases [30, 31]. LM-procured 
cells have also allowed the detection of proteome alterations in several diseases affecting 
heterogeneous tissues such as prostate, ovary, oesophagus and breast tissues [16-20, 29, 32, 33] 
using 2-DE methodology. With respect to the liver, two proteome studies carried out with 
microdissected hepatocytes have so far been published [21, 22]. However, the actual benefits of 
incorporating LM when testing for proteome alterations during liver diseases such as HCC 
developing in a setting of cirrhosis have not been established because comparative studies using 
LM-hepatocytes and total homogenates have not been assessed.  
The accurate microdissection of hepatocytes requires the staining of tissue slides with both 
haematoxylin and eosin, the only staining method appropriate for accurate microscopic 
characterization of the different cell types present in the liver. But haematoxylin/eosin staining 
may have detrimental effects on 2-DE protein profiles ([29] and results not shown) and the 
accurate identification of proteins by mass peptide fingerprinting [34], because eosin may 
establish covalent links with proteins [35, 36]. We thus optimised several steps of this staining 
method: under these conditions, the 2-DE profiles established using stained liver sections or 
  
 
 
microdissected liver cells, and the peptide spectra acquired during mass spectrometry for each 
protein, did not suffer from any further alternations, thus suggesting proteome analysis could be 
performed accurately on liver sections stained with haematoxylin/eosin. 
Using bioinformatics tools, 786 proteins with the same coordinates were detected in 2-DE gels 
performed using total liver homogenates and LM-hepatocytes. The validity of the method used to 
establish these maps was proved by the mass spectrometry identification of the same proteins in 
spots with the same coordinates under both conditions (see below).  
Differential protein profiles determined using microdissected cells and global homogenates 
exhibited noticeable differences: 30% of protein spots which showed deregulated expression in 
tumorous LM-hepatocytes did not display significant alterations in homogenates-based 
experiments; conversely, 15% of proteins differentially expressed in tumorous homogenates did 
not display significant alterations in LM- hepatocytes.  
These data suggest that fibrotic stroma which was not collected during hepatocyte 
microdissection in cirrhotic livers could alter the proteomic patterns. Several lines of evidence 
supported this observation. As illustrated in Figure 3, numerous differences were detected 
between protein profiles determined using LM- hepatocytes and homogenates from non-
tumorous cirrhotic areas which included inflammatory infiltrates and fibrosis (Figure 5A). 
Furthermore, selective microdissections of fibrotic stroma and hepatocyte compartments (Figure 
5B) made it possible to demonstrate that protein expression differed between fibrotic stroma and 
hepatocytes . 
Thus, protein expression in homogenates reflected the relative abundance of hepatocytes and 
stromal cells in the samples analysed.  Moreover, when the experiments were carried out with 
LM-hepatocytes, the selection of spots deregulated in the tumour was improved: as shown in 
  
 
 
Figure 6, the expression ratios between tumorous and non-tumorous samples were significantly 
higher when determined using LM-hepatocytes (p<0.001). 
Proteins with deregulated expression in tumour detected in LM-hepatocytes and/or in 
homogenates were identified using MALDI–MS. Forty five different proteins with deregulated 
expression in tumour were identified with confidence from spots picked out on 2-DE gels 
obtained with LM-hepatocytes and global homogenates; this suggests our experimental 
procedures for staining and microdissection did not further impair protein identification, as in the 
case of 2-DE profiles. Four proteins were identified as being two isoforms with similar 
electrophoretic mobility and different pHi: HSP 27, Tissue transglutaminase, Heat shock cognate 
71 kDa protein and fumarylacetoacetase. isoform expression in tumour differed in two of them: 
both isoforms of the Heat Shock Cognate 71 kDa protein were increased in homogenates but only 
one was upregulated in LM-hepatocytes, while for fumarylacetoacetase, one isoform was down-
regulated under both conditions but the other was only up-regulated in homogenates. Western 
blot analysis of the proteins exhibiting different expression profiles in LM- hepatocytes and 
homogenates confirmed these analyses (Figure 4). Thus the use of LM enabled the accurate study 
of proteomic alterations in fibrotic stroma as well as in tumorous and non-tumorous hepatocytes.  
To date, only two other studies using LM-hepatocytes have investigated proteome alterations in 
HCC [21, 22] and few common deregulated proteins were counted when their findings were 
compared with our data.  Several explanations can be put forward to explain these apparent 
discrepancies. The patients included in those studies were infected with HBV and it was reported 
that etiological factors imprinted the expression pattern of proteome in HCC tissues [9].  
Elsewhere, Ai et al. [21] only retained ten deregulated proteins in their study. Moreover, the 
strategy adopted by Li et al. [22] based on 2D-LC-MS/MS investigated a scale of proteins it was 
difficult to achieve with 2-DE/MS experiments. 
  
 
 
Of the 40 proteins identified in our study as being deregulated in LM-hepatocytes, 33 had been 
reported as being altered in HCC during 2-DE/MS experiments carried out on homogenates 
(Table 1). Our study and the aforementioned publications demonstrated the same alteration 
patterns for all but five of these proteins (isocitrate dehydrogenase, tissue transglutaminase, 
adenosyl homocysteinase, annexin A6 and annexin A1). Further studies need to be performed to 
clarify these discrepancies. Of note, and as illustrated in our study by the case of 
fumarylacetoacetase [9], distinct isoforms could exhibit different variations in LM-hepatocytes 
and homogenates.  
 
In conclusion, our data taken together demonstrate that LM enables a comparison of hepatocyte 
proteome alterations in patients whose HCC has developed in a variable fibrotic context; 
moreover, by specifically isolating the fibrotic stroma, these findings may also provide insights 
into the pathogenesis of fibrosis and the role of the microenvironment. During this study, LM 
was associated with 2-DE in order to evidence quantitative proteomic alterations in HCC. 
However, 2-DE analysis requires large quantities of proteins which are not easily procured using 
LM.  For this reason, it will now be necessary to combine this technique with other methods 
requiring smaller amounts of protein in order to exploit the benefits of LM methodology. By 
establishing the necessary methodological procedures, our study has paved the way to achieving 
such improvements. 
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Figures and table legends 
Figure 1: The effects of hematoxylin/eosin staining and laser microdissection on 2-DE 
profiles.   
A- 2-DE profiles were performed using unprocessed, stained tissue slides and cells 
microdissected from stained slides after optimisation of the staining procedure. B- Scatter plots 
showing the correlation between the relative volumes (means of 3 gels) of protein spots 
determined using 2-DE and carried out with unprocessed and stained tissue slides (left) and 
stained tissue slides and microdissected cells (right). The correlation coefficients calculated were 
determined according to Spearman.  
 
Figure 2: Comparison of differential protein expression profiles established using LM-
procured hepatocytes and total liver homogenate.  
A- Left: Differential protein profile determined during 2-DE performed with LM-procured 
hepatocytes: 146 protein spots were differentially expressed (white) and 640 were not altered 
(black) in tumorous hepatocytes. Right: the 146 protein spots deregulated in tumorous 
hepatocytes were analysed in global homogenate samples: 95 were similarly deregulated (white), 
8 were deregulated in an opposite way (grey) and 43 were not altered (black).  B- Left: 
Differential protein profile determined during 2-DE performed with global homogenates: 119 
protein spots were differentially expressed (white) and 667 were not altered (black) in tumorous 
homogenate. Right: the 119 protein spots deregulated in tumorous global homogenates were 
analysed in LM-hepatocytes samples: 95 were similarly deregulated (white), 8 were deregulated 
in an opposite way (grey) and 16 were not altered (black) 
 
  
 
 
Figure 3: Comparative analysis of relative 2-DE spot volumes in LM-hepatocytes (black 
bars) and total liver homogenate (white bars) experiments. 
Representative examples of spots with deregulated differently in tumorous (T) and non tumorous 
(NT) counterparts. Data are expressed as means ± SEM of three experiments. Statistical analysis 
was performed using the Mann-Whitney U-test and Student’s t-test. NS: non-significant 
 
Figure 4: Western blot analysis of MxA, Annexin A1, mitochondrial HMGCoA synthase 
and GRP75 in both homogenate and LM-hepatocyte samples. 
Western blots were performed as described in the Material and Methods using paired tumour (T) 
and non-tumour (NT) pooled samples from the three patients included in 2-DE experiments. 
 
Figure 5: Analysis of Arginase 1 and mitochondrial HMG CoA synthase in global 
homogenates, stromal cells and hepatocytes selected by microdissection in the non-
tumorous area. 
A. Non tumorous liver section stained with H&E shows the abundance of fibrotic stroma (F) in 
the cirrhotic liver. Hepatocyte nodules are mentioned as H.  
B- Fibrotic stroma and hepatocytes were microdissected in the non tumorous area of liver from 
two patients.  Levels of Arginase 1 and mitochondrial HMG CoA synthase expression were 
analysed as described in the Materials and Methods in fibrotic stroma (F), hepatocytes (H) and 
complete homogenates (C) for each patient.  
 
Figure 6: Range of T/NT expression ratios of the spots similarly deregulated in tumorous 
LM-hepatocytes and total liver homogenates  
On the absciss are the 95 spots similarly deregulated in tumorous samples. On the ordinates, (A) 
  
 
 
T/NT expression ratios of protein spots deregulated in tumorous LM-hepatocytes and (B) T/NT 
ratios of protein spots deregulated in tumorous homogenates. Expression ratios of each spot 
determined under both conditions were compared using the match-paired Wilcoxon rank test. 
Statistical analysis showed that T/NT ratios were significantly increased when measured in LM-
hepatocytes (p<0.001). 
 
Table 1: Proteins differentially expressed in tumorous LM-hepatocytes and total 
homogenate samples identified by mass peptide fingerprinting.  
a) Spot id on gel refers to the synthetic gel used for comparison. b) A positive ratio indicates 
over-expression in the tumour, whereas a negative ratio indicates under-expression in the tumour. 
c) Bibliographical reference for proteins already described in human liver carcinogenesis using 
proteomic or specific studies. d) NS: non-significant 
 
Supplemental Data 
Figure 1: Microdissection of hepatocytes in cirrhotic nodules. 
Stained liver sections before (A) and after (B) the laser microdissection of hepatocyte nodules. 
Captured cluster of hepatocytes (C).  
 
Figure 2: Western blot analysis of MxA, cathepsin D, nicotinamide N-methyltransferase 
and tissue transglutaminase in global homogenates, stromal cells and hepatocytes selected 
using microdissection in the non tumorous area. 
Fibrotic stroma and hepatocytes were microdissected in the non tumorous area of liver from two 
patients. Western blots were performed in fibrotic stroma (F), hepatocytes (H) and complete 
homogenates (C) for each patient as described in the Materials and Methods. 
